

Cancer stem cell plasticity as tumor growth promoter and catalyst of population collapse

Jan Poleszczuk*, Heiko Enderling

Department of Integrated Mathematical Oncology, H. Lee Moffitt Cancer Center &
Research Institute, 12902 Magnolia Drive, Tampa, FL, USA

Corresponding author*: jan.poleszczuk@moffitt.org

Abstract

It is increasingly argued that cancer stem cells are not a cellular phenotype but rather a transient state that cells can acquire, either through intrinsic signaling cascades or in response to environmental cues. While cancer stem cell plasticity is generally associated with increased aggressiveness and treatment resistance, we set out to thoroughly investigate the impact of different rates of plasticity on early and late tumor growth dynamics and the response to therapy. We develop an agent-based model of cancer stem cell driven tumor growth, in which plasticity is defined as a spontaneous transition between stem and non-stem cancer cell states. Simulations of the model show that plasticity can substantially increase tumor growth rate and invasion. At high rates of plasticity, however, the cells get exhausted and the tumor will undergo spontaneous remission in the long term. In a series of *in silico* trials we show that such remission can be facilitated through radiotherapy. The presented study suggests that stem cell plasticity

has rather complex, non-intuitive implications on tumor growth and treatment response. Further theoretical, experimental and integrated studies are needed to fully decipher cancer stem cell plasticity and how it can be harnessed for novel therapeutic approaches.

Introduction

After stem cells have been discovered at the top of the hematopoietic system hierarchy [1], it became apparent that human acute myeloid leukemia is also organized hierarchically. Leukemia is initiated and fueled by a leukemic stem cell that gives rise to transit-amplifying progenitor cells and eventually differentiated cancer cells with limited lifespan [2]. A cellular hierarchy in a tumor and the accompanying stem cell hypothesis has been hailed as a significant breakthrough in the cancer research community, as its concept holds new promises for cancer therapy. If only CSC are uniquely able to initiate, sustain and propagate a tumor, then selective eradication of CSC – however difficult it might be to target them – would be sufficient to cure a cancer [3]. Despite its conceptual beauty, recent reports consolidated the skepticism that stemness might not be a prescribed cell phenotype but a transient state that cells can acquire and discard dependent on the cellular environment and signaling context [4-7]. Then the heterogeneous tumor population becomes a dynamic, moving target that is increasingly difficult to treat [8].

The complex biology of stem and non-stem cancer cells and their interactions with each other as well as with the intra- and extratumoral environment is yet to be fully deciphered experimentally. Inroads have been made to use mathematical and computational models to identify first-order principles and key biological mechanisms in cancer plasticity, from

which new actionable hypotheses can be derived [7, 9-12]. Herein we propose an *in silico* agent-based computational model to help decipher parts of the complexity that arises from the myriads of stem and non-stem cancer cell interactions and phenotypic plasticity. Agent-based models are increasingly utilized in theoretical oncology [13-20] to derive emerging population level dynamics from defined single cell properties and their perturbation. Such modeling approach has previously shown that the proliferation capacity (or telomere length [21, 22], or Hayflick limit [23, 24]) of non-stem cancer cell (CC) is a pivotal force in driving tumor evolution [25, 26]. Then, early progenitor cells that adapt a stem cell state confer different kinetic properties including proliferation potential to the new stem cell than de-differentiating cells that are closer to their terminal phenotype.

The role of the cellular hierarchy in a tumor has been widely ignored in the modeling community, such that CC that transition into a CSC have the same properties as the initial population-founding CSC. Thus, in addition to conferring the general CSC traits of (a)symmetric division and longevity, the new CSC gets also bestowed with the historic initial telomere length with the stupendous consequences of increased aggressiveness and treatment failure. Herein we give explicit consideration of the degrading proliferative potential in the cellular hierarchy in a phenotypic plasticity model. We show that phenotypic plasticity promotes early tumor growth; in the long-term, however, plasticity can impede tumor progression and ultimately lead to the collapse of the tumor population. We will use radiotherapy as an example of an external catalyst to eventual complete remission.

Materials and Methods

Mathematical model

We adapt an *in silico* agent-based model [26, 27], in which each cancer cell occupies a $10 \times 10 \mu\text{m}$ grid point on a dynamically expanding 2D lattice [28]. A dynamic computational domain prevents boundary-imposed spatial constraints that may influence outcomes.

The tumor population is divided into cancer stem cells (CSCs) and non-stem cancer cells (CCs) with an individual proliferation capacity, ρ , representative of the telomere length [21, 29]. Telomeres are shortened during mitosis [22, 30] reducing the proliferation capacity in each daughter cell ($\rho-1$), which is a visualization of the Hayflick limit [24, 31]. CSCs are believed to upregulate telomerase which rebuilds telomeric DNA and thus prevents telomere erosion and confers longevity to the cell [32-35]. We assume a cell with exhausted proliferation capacity ($\rho=0$) to undergo cell death in the next mitotic attempt as previously assumed [25, 36] without explicit consideration of replicative senescence [18, 37]. In addition to replicative cell death we consider spontaneous cell death in CC with probability α , which is prevented in CSC. Without considering cell plasticity, CC and CSC populations are only connected through asymmetric division of a CSC, when one of the progeny adopts a CC phenotype (Fig. 1A). We denote the probability of symmetric CSC division by p_s . Plasticity may occur at successful proliferation with probabilities p_d (CSC differentiation) and p_{dd} (CC de-differentiation). If $p_d=p_{dd}=0$, plasticity is averted and cells have a persistent phenotype. With $p_d>0$ and $p_{dd}>0$, cell phenotypes are plastic and stemness becomes a transient state. We note that

stemness is defined by the ability to divide (a)symmetrically and prevention of telomere erosion [34, 38]. Therefore, a CC that adopts a CSC state through dedifferentiation will be equipped with current telomere length, i.e. ρ , which will be bequeathed to subsequent daughter cells (Fig. 1B). This is in stark contrast to previous modeling attempts that in addition to conferring general CSC traits also re-set time and equip new CSC with historic uniform initial telomere length.

At discrete simulation time steps representative of $\Delta t = 1$ hour, cell are randomly selected and updated. In case of a CC, spontaneous cell death is considered with probability α . Proliferation and migration of surviving cells are mutually exclusive ($p_p=1/24$, i.e. once per day; $p_m=15/24$, i.e. 150 μm per day) subject to available space in the immediate cell neighborhood. The simulation procedure is summarized in a flowchart in Fig. 1C.

Tumor morphology analysis

In case of frequent migration events, defining tumor periphery on a two-dimensional lattice is not straightforward, as cells may separate from the main tumor mass. In order to define the tumor periphery we first transform the lattice into binary information (cell present or not). Then we substitute the value of each pixel by the average number of positive pixels in the immediate 8-neighbors Moore neighborhood, and apply an image intensity threshold of 3/8 (this includes vacant sites with more than 2 cancer cells in the neighborhood) and select regions containing more than 10^4 cells. We define the tumor periphery as the periphery of the selected regions. All transformations are made using MATLAB with Image Processing Toolbox.

Tumor circularity is calculated as

$$Circularity = \frac{4\pi A}{S^2},$$

where A is the tumor area and S is the perimeter length. For a perfect circle the circularity is equal to 1. Both A and S are calculated using the *regionprops* function from the MATLAB Image Processing Toolbox.

In order to calculate the CSC fraction in the proximity of the tumor boundary, we dilate the tumor periphery by 20 pixels in four orthogonal directions and select all cells within the dilated area. This procedure selects cells that are within 200 μm in from the tumor boundary.

Metastatic potential

We estimate the potential for metastatic spread using a virtual 5-well plate, where wells are connected sequentially by a narrow canal of 100 μm width and 400 μm length. Each well is circular with a 50 μm diameter. Each simulation is initiated with a single CSC in the geometric center of the first well. Metastatic spread is simulated until the first CSC enters the last blind-ended canal.

Radiotherapy

We simulate fractionated radiotherapy of 30 fractions of dose $d=2$ Gy applied every 24h hours. The dose-dependent surviving fraction $SF(d)$ is calculated using the linear-quadratic formalism

$$SF(D) = e^{-\xi\lambda(aD+bD^2)},$$

where $\xi < 1$ describes radioresistance of quiescent cell, i.e. for cell with no available space in the neighborhood, and $\xi = 1$ otherwise, and $\lambda < 1$ describes increased radioresistance of CSC [39, 40]. For CC, $\lambda = 1$. In line with previous estimates we set $\xi = 0.5$, $\lambda = 0.1376$, $a = 0.3859$ and $b = 0.01148$ [40].

Results and Discussion

We initiate each simulation with a single CSC with proliferation capacity $\rho = 10$ and probability of symmetric division $p_s = 1\%$, and simulate tumor growth for 720 days. We consider bidirectional plasticity with equal probabilities $p_d = p_{dd} = 0\%$ (static phenotypes), 0.01%, 0.1%, 1% and 10%. For each set of parameters we performed 100 simulations, and statistical analyses were performed using the Student's t-test.

Impact of plasticity on tumor growth characteristics

Phenotypic plasticity increases initial tumor growth rate yielding larger tumors after 720 days than the tumors with static phenotypes (Fig. 2A). However, for larger plasticity ($p_d = 10\%$), tumor growth saturates around day 320 keeping the tumor in a dormant state followed by a decrease in total cell number. In contrast to initial growth that is favored by higher plasticity rates, increasing phenotypic plasticity inhibits tumor growth later. This population level behavior mimics the evolution of CSC number (Fig. 2B) and ratio (Fig. 2C). CSC fraction in phenotypic plasticity tumors appears to saturate around the value of 50% for all considered transition rates, but this ratio is only achieved in the considered time frame with $p_d = p_{dd} = 10\%$.

In addition to increasing the average tumor size during the growth phase, plasticity reduces the amount of variation in tumor size (Fig. 2D). For $p_d = 1\%$, standard deviation is only 20% at $t=720$ days, compared to 3 times larger S.D.=60% for tumors with static phenotypes. The source of variation in tumor size across independent simulation is opportunistic competition for available space between CSC and CC in the tumor interior where most CSC are located without plasticity [19, 25, 36, 41]. Phenotypic plasticity partially averts intratumoral CSC inhibition and prolonged phases of population-level dormancy [42] as new CSC are continuously created at the boundary with fewer spatial constraints.

Interestingly, in case of $p_d = 0.1\%$ one simulate tumor died spontaneously early during development. In that simulation, the initial CSC differentiated before the first stochastic symmetric division event, and all of its CC progenies died before a de-differentiation event. In the Appendix we show analytically that the probability of that event is approximately 0.5% for all considered plasticity rates and, thus, is large enough to manifest in numerical simulations.

To analyze analytically if tumors with phenotypic plasticity can undergo spontaneous remission, we first consider the possible division fates of a CSC with proliferation capacity i (CSC_i). With probability p_d the CSC will differentiate before a symmetric division and it will be lost. In case of a de-differentiation event of a CC, the new CSC will have a proliferation capacity $\rho < i$ (Fig. 3A). If the CSC divides symmetrically, a

new CSC_i will be created. In case of asymmetric division we need to follow the fate of the CC progeny. At each iteration, the CC can die spontaneously with probability α . Let us denote by α' the probability that the newly created CC will die before a proliferation attempt ($\alpha' \geq \alpha$). Then, no new CSC_i will be created with probability α' . If the CC divides, a new CSC_i is only created in case of a de-differentiation event with probability p_{dd} . If after de-differentiation the CSC_i undergoes symmetric division, then two new CSC_i are created. This theoretical consideration has four possible outcomes: the number of CSC_i 1) decreases with probability $p_1 = p_d$, 2) remains the same with probability $p_2 = (1-p_d)(1-p_s)[\alpha' + (1-\alpha')(1-p_{dd})]$, 3) increases by one with probability $p_3 = (1-p_d)[p_s + (1-p_s)(1-\alpha')p_{dd}(1-p_s)]$, and 4) increases by two with probability $p_4 = (1-p_d)(1-p_s)(1-\alpha')p_{dd}p_s$. Hence, the probability P that all CSC_i will die after the initial seeding of one CSC_i fulfills the relation $P = p + qP^2 + (1-p-q)P^3$, where $p = p_1/(p_1+p_3+p_4)$ and $q = p_3/(p_1+p_3+p_4)$, from which we obtain that

$$P = \min \left\{ \frac{p - 1 + \sqrt{-3p^2 - 4pq + 2p + 1}}{2(1-p-q)}, 1 \right\}. \quad (A)$$

Obviously for $p_d = 0$, i.e. no possible differentiation event, we have $P = 0$, and for $\alpha' = 1$ the problem reduces to $P = \min\{(1-q)/q, 1\}$. Importantly, if $P = 1$, then all CSC will die off regardless of the initial number of CSC. Eqn. (A) contains only one unknown parameter, α' , which depends on the extend of spatial inhibition and the proliferation probability p_p . However, the probability, p , is an increasing function of α' , and $\alpha' \geq \alpha$. Thus, if a tumor dies spontaneously with probability 1 for $\alpha' = \alpha$, then it also dies spontaneously with probability one for any larger α' . Similarly, if $P < 1$ for $\alpha' = 1$, then the tumor will not die spontaneously in each single simulation iteration. It is worth to

mention that a non-zero value of parameter α is crucial for relating the agent-based model to probability P , as the average time between the CSC proliferation events can grow without bound if $\alpha = 0$, due to intratumoral spatial inhibition.

Fig. 3B shows the probability P of a CSC population vanishing for $\alpha' = 1$ and $\alpha' = 0.01$ if $p_d = p_{dd}$. All simulated tumors will eventually die off spontaneously for p_d values larger than $\approx 9.09\%$. This explains the previously observed decrease in the average tumor size for $p_d = 10\%$ (c.f., Fig. 2A). For $p_d = 0.1\%$ in the initially presented tumor growth simulations, $P \sim 0.1$ for $\alpha' = 1$, and thus about 90% of tumors will grow successfully.

Let us consider 100 independent simulations initialized with CSC_3 and $p_d = p_{dd} = 10\%$. As predicted by the above theory, all 100 tumors will undergo remission as $P = 1$ in that case (Fig. 3C). Increase the probability of symmetric division from $p_s = 1\%$ to $p_s = 3\%$, only 17 of 100 tumors die out (Fig. 3D). However, the above theory cannot conclusively predict if all of these tumors will eventually die off.

Impact of plasticity on tumor morphology

Fig. 4A shows the largest tumors after simulated 720 days of 100 independent simulations for different plasticity probabilities. Although the average tumor size for $p_d = 10\%$ is larger than for $p_d = 0\%$ (c.f., Fig. 1A), the biggest simulated tumor is smaller (114,950 vs. 283,504 cells). This is a manifestation of the larger coefficient of variation in the static phenotype cohort (c.f., Fig. 1D).

The morphology of tumors with static phenotypes is described as self-metastatic [36] with low circularity [43]. Tumors with intermediate plasticity probabilities, $p_d=0.1\%$ and $p_d=1\%$, feature a regular, almost circular morphology at day 720 as the self-metastatic morphology caused by the spatial inhibition of CSCs is averted by spontaneous CCs de-differentiation at the tumor periphery (Fig. 4B). For larger plasticity probabilities ($p_d = 10\%$), clusters of cells at the tumor periphery die off stochastically, which yields a less regular boundary and decreasing tumor circularity.

Low values of plasticity probabilities ($p_d=0.1\%$ and $p_d=1\%$) are associated with a five-fold increase in the fraction of quiescent cells compared to tumors with static phenotypes, arguably at least in part due to the larger size and thus reduced surface-to-volume ratio (Fig. 4C). For $p_d = 10\%$ the exhaustion and spontaneous death of CC is not effectively filled and thus a larger proportion of cells is actively proliferating, which is comparable to the one in the non-plastic tumor.

A monotonic dependence on plasticity probability is the fraction of cancer stem cells in the proximity of the tumor boundary (Fig. 4D). For $p_d = 10\%$, more than 50% of the CSC are close to the tumor boundary, which represents almost the entire cancer stem cell fraction (c.f. Fig. 2C). The prevalence of CSC in the tumor periphery suggests that plasticity may lead to increased potential for metastatic spread.

Impact of plasticity on invasiveness

For each considered value of plasticity probability we simulated 100 virtual 5-well plate experiments. For $p_d = 0\%$, 0.1% and 1% , in all simulations a CSC successfully reached the right boundary of the experimental setup. However, for $p_d = 10\%$ as many as 97 out of 100 simulations ended with spontaneous death of all cancer cells before invading all wells. Time to reach the right boundary was significantly lower in all plastic tumors, with almost 1.5-fold and 2-fold reduction for $p_d = 0.1\%$ and $p_d = 1\%$, respectively, when compared to tumors with static phenotypes (Fig. 5A). However, the invasion speed follows a non-monotonic behavior in plastic populations, as the time needed to reach right boundary for is reduced for $p_d = 1\%$ compared to both $p_d = 0.1\%$ and $p_d = 10\%$, indicating a exhaustion of the population as discussed above.

Visualizations of successful simulations show a plasticity-dependent gradient of cancer stem cell fraction values in subsequent wells (Fig. 5B). With lower values of plasticity the difference between the composition of population in the first and the last well increases, with about 16-fold change for non-plastic tumor. For the largest considered value of $p_d = 10\%$, however, there is no significant difference in composition between the wells.

Impact of plasticity on the radiation outcome

We simulated the impact of radiotherapy on tumors consisted of 250,000 cells generated for different plasticity probabilities. As expected, the tumor without plasticity responds best to radiotherapy (Fig. 6A), as it has the smallest fraction of CSC with decreased radiosensitivity λ (c.f., Fig. 2C) and small proportion of quiescent cells with decreased

radiosensitivity ξ (c.f., Fig. 4C). The tumors with relatively low plasticity, $p_d=0.1\%$ and $p_d=1\%$, show similar response to radiation, with number of cells reduced about 20 times compared to the pre-treatment state. Tumor with the highest plasticity event probability, $p_d = 10\%$, shows an intermediate response, what can be explained by lower fraction of quiescent cells compared to other plastic tumors (Fig. 4C) and larger fraction of stem cells compared to the plasticity free tumor (Fig. 2C). However, in none of simulations tumor was eradicated during the course of treatment.

Simulations of tumor growth following the treatment show that for tumors without and with low plasticity show regrowth to pre-treatment cell counts within 200 days after the onset of treatment (Fig. 6B). However, all of the simulated tumors with $p_d = 10\%$ undergo spontaneous remission (Fig. 6C) within two years after transient regrowth. Radiotherapy on highly plastic tumors may serve as an accelerator of CSC exhaustion due to frequent differentiation events with subsequent loss of proliferation potential.

Conclusions

The observation of cancer stem cell plasticity has lead to the general belief of more aggressive tumor growth and reduced treatment response [12]. We introduced an *in silico* agent-based model of cancer stem cell driven tumor growth to study the impact of different rates of phenotypic plasticity on tumor growth, morphology, invasion and treatment response. Simulations of our model show that plasticity accelerates early tumor growth, as prolonged phases of tumor dormancy due to intratumoral competition [42] is averted by cells on the periphery acquiring stem cell traits and propagating the tumor

population. Whilst tumors with fixed phenotypes show a gradual increase in CSC over time, phenotypic plasticity yields relatively constant population fractions, with CSC predominantly located at the tumor boundary – thereby facilitating invasion and metastatic spread. The explicit consideration of the cellular hierarchy within a tumor and the accompanying reduction of proliferation potential, however, offer a previously unappreciated aspect of CSC plasticity. Transitions between stem and non-stem cancer cell states at high frequencies yield a reduction of proliferation potential in each cell, thereby reducing the lifespan of each daughter cell and inevitably cell death. This may lead to population level dormancy and ultimately collapse of the tumor with complete remission.

Mathematical and computational models, by virtue of their very purpose, are subject to gross oversimplifications of reality [44]. However, they may provide interesting and non-intuitive insights into the tumor progression dynamics, including novel discussion points in understanding cancer stem cell plasticity. Further theoretical, experimental and integrated studies are needed to fully decipher cancer stem cell plasticity and how it can be harnessed for novel therapeutic approaches.

Acknowledgments

JP would like to thank the Foundation for Polish Science for partial support.

References

1. Becker AJ, McCulloch EA, Till JE: **Cytological demonstration of the clonal nature of spleen colonies derived from transplanted mouse marrow cells.** *Nature* 1963,

197:452–454.

2. Bonnet D, Dick JE: **Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell.** *Nat Med* 1997, **3**:730–737.
3. Reya T, Morrison SJ, Clarke MF, Weissman IL. **Stem cells, cancer, and cancer stem cells.** *Nature* 2001, **414**:105–111.
4. Poulsom R, Alison MR, Forbes SJ, Wright NA: **Adult stem cell plasticity.** *J Pathol* 2002, **197**:441–456.
5. Wagers AJ, Weissman IL: **Plasticity of adult stem cells.** *Cell* 2004, **116**:639–648.
6. Rapp UR, Ceteci F, Schreck R: **Oncogene-induced plasticity and cancer stem cells.** *Cell Cycle* 2008, **7**:45–51.
7. Wang L, Walker BL, Iannaccone S, Bhatt D, Kennedy PJ, Tse WT: **Bistable switches control memory and plasticity in cellular differentiation.** *Proc Natl Acad Sci USA* 2009, **106**:6638–6643.
8. Schwitalla S: **Tumor cell plasticity: the challenge to catch a moving target.** *J Gastroenterol* 2014, **49**:618–627.
9. Gao X, McDonald JT, Naidu M, Hahnfeldt P, Hlatky LR: **A proposed quantitative index for assessing the potential contribution of reprogramming to cancer stem cell kinetics.** *Stem Cells Int* 2014, **2014**:249309–8.
10. Leder K, Pitter K, Laplant Q, Hambarzumyan D, Ross BD, Chan TA, Holland EC, Michor F: **Mathematical modeling of PDGF-driven glioblastoma reveals optimized radiation dosing schedules.** *Cell* 2014, **156**:603–616.
11. Gupta PB, Fillmore CM, Jiang G, Shapira SD, Tao K, Kuperwasser C, Lander ES: **Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells.** *Cell* 2011, **146**:633–644.
12. Leder K, Holland EC, Michor F. **The Therapeutic Implications of Plasticity of the Cancer Stem Cell Phenotype.** *PLoS One* 2010, **5**:e14366.
13. d'Inverno M, Howells P, Montagna S, Roeder I, Saunders R: **Agent-Based Modeling of Stem Cells.** In *Multi-Agent Systems Simulation and Applications*; 2009:389–418.
14. Pepper JW, Vydelingum NA, Dunn BK, Fagerstrom RM: **Agent-based models in cancer prevention research.** In *Advances in Computational Modeling Research*. Edited by Kora AB; 2013:105–115.
15. Tang J, Enderling H, Becker-Weimann S, Pham C, Polyzos A, Chen C-Y, Costes SV: **Phenotypic transition maps of 3D breast acini obtained by imaging-guided agent-based modeling.** *Integr Biol (Camb)* 2011, **3**:408–421.

16. Wang Z, Butner JD, Kerketta R, Cristini V, Deisboeck TS: **Simulating cancer growth with multiscale agent-based modeling.** *Semin Cancer Biol* 2014.
17. Kareva I: **Immune evasion through competitive inhibition: the shielding effect of cancer non-stem cells.** *J Theor Biol* 2014.
18. Poleszczuk J, Hahnfeldt P, Enderling H: **Biphasic modulation of cancer stem cell-driven solid tumour dynamics in response to reactivated replicative senescence.** *Cell Prolif* 2014, **47**:267–276.
19. Alfonso JCL, Jagiella N, Núñez L, Herrero MA, Drasdo D: **Estimating dose painting effects in radiotherapy: a mathematical model.** *PLoS ONE* 2014, **9**:e89380.
20. Li F, Tan H, Singh J, Yang J, Xia X, Bao J, Ma J, Zhan M, Wong STC: **A 3D multiscale model of cancer stem cell in tumor development.** *BMC Syst Biol* 2013, **7** Suppl 2:S12.
21. Blackburn EH, Gall JG: **A tandemly repeated sequence at the termini of the extrachromosomal ribosomal RNA genes in Tetrahymena.** *J Mol Biol* 1978, **120**:33–53.
22. Harley CB: **Telomere loss: mitotic clock or genetic time bomb?** *Mutation ResearchDNAging* 1991, **256**:271–282.
23. Hayflick L, Moorhead PS: **The serial cultivation of human diploid cell strains.** *Exp Cell Res* 1961, **25**:585–621.
24. Hayflick L: **The limited in vitro lifetime of human diploid cell strains.** *Exp Cell Res* 1965, **37**:614–636.
25. Morton CI, Hlatky LR, Hahnfeldt P, Enderling H: **Non-stem cancer cell kinetics modulate solid tumor progression.** *Theor Biol Med Model* 2011, **8**:48.
26. Poleszczuk J, Hahnfeldt P, Enderling H: **Evolution and phenotypic selection of cancer stem cells.** *PLoS Comput Biol* 2014:1–28.
27. Enderling H, Anderson ARA, Chaplain MAJ, Beheshti A, Hlatky LR, Hahnfeldt P: **Paradoxical dependencies of tumor dormancy and progression on basic cell kinetics.** *Cancer Res* 2009, **69**:8814–8821.
28. Poleszczuk J, Enderling H: **A High-Performance Cellular Automaton Model of Tumor Growth with Dynamically Growing Domains.** *Applied Mathematics* 2014, **5**:144–152.
29. Greider CW, Blackburn EH: **Identification of a specific telomere terminal transferase activity in Tetrahymena extracts.** *Cell* 1985, **43**:405–413.
30. Olovnikov AM: **A theory of marginotomy. The incomplete copying of template**

margin in enzymic synthesis of polynucleotides and biological significance of the phenomenon. *J Theor Biol* 1973, **41**:181–190.

31. Hayflick L. **The serial cultivation of human diploid cell strains.** *Exp Cell Res* 1961, **25**:585–621.

32. Allsopp RC, Morin GB, DePinho R, Harley CB, Weissman IL: **Telomerase is required to slow telomere shortening and extend replicative lifespan of HSCs during serial transplantation.** *Hematopoiesis* 2003, **102**:517–520.

33. Armanios M, Greider CW: **Telomerase and cancer stem cells.** *Cold Spring Harb Symp Quant Biol* 2005, **70**:205–208.

34. Ju Z, Rudolph KL: **Telomeres and telomerase in cancer stem cells.** *Eur J Cancer* 2006, **42**:1197–1203.

35. Shay JW, Wright WE. **Telomeres and telomerase in normal and cancer stem cells.** *FEBS Lett* 2010, **584**:3819–3825.

36. Enderling H, Hlatky LR, Hahnfeldt P: **Migration rules: tumours are conglomerates of self-metastases.** *Br J Cancer* 2009, **100**:1917–1925.

37. Campisi J, Kim SH, Lim CS, Rubio M: **Cellular senescence, cancer and aging: the telomere connection.** *Exp Gerontol* 2001, **36**:1619–1637.

38. Dingli D, Traulsen A, Michor F: **(A)symmetric stem cell replication and cancer.** *PLoS Comput Biol* 2007, **3**:e53.

39. Enderling H, Park D, Hlatky LR, Hahnfeldt P: **The Importance of Spatial Distribution of Stemness and Proliferation State in Determining Tumor Radioresponse.** *Math Model Nat Phenom* 2009, **4**:117–133.

40. Gao X, McDonald JT, Hlatky LR, Enderling H: **Acute and fractionated irradiation differentially modulate glioma stem cell division kinetics.** *Cancer Res* 2013, **73**:1481–1490.

41. Sottoriva A, Verhoeff JJC, Borovski T, McWeeney SK, Naumov L, Medema JP, Sloot PMA, Vermeulen L: **Cancer stem cell tumor model reveals invasive morphology and increased phenotypical heterogeneity.** *Cancer Res* 2010, **70**:46–56.

42. Enderling H: **Cancer stem cells and tumor dormancy.** *Adv Exp Med Biol* 2013, **734**:55–71.

43. Enderling H, Hlatky LR, Hahnfeldt P: **Cancer Stem Cells: A Minor Cancer Subpopulation that Redefines Global Cancer Features.** *Front Oncol* 2013, **3**:76.

44. Enderling H: **Cancer stem cells: small subpopulation or evolving fraction?** *Integr Biol (Camb)* 2014, **7**:14–23.

Figure legends

Figure 1. **A)** Schematic of the proliferation potential erosion in the non-cancer cell (CC) population after asymmetric division of cancer stem cell (CSC) that occurs with probability p_s . **B)** Schematic of cellular differentiation and de-differentiation (probabilities p_d and p_{dd} , respectively), in which the proliferation potential is memorized in course of evolution. **C)** Schematic of the simulation procedure and cell cycle evaluations.

Figure 2. Average total cell count (A), cancer stem cell, CSC, number (B) and fraction (C), and coefficient of variation, i.e. standard deviation/mean, for the total cell count (D) as a function of time for tumor without plasticity ($p_d = 0\%$, blue solid curve) and with plasticity probability of 0.1% (red dashed curve), 1% (yellow dot-dashed curve) and 10% (purple dotted curve). Shown are means from 100 simulation runs (only successfully grown tumors are considered). Error bars omitted for clarity.

Figure 3. (A) Possible outcomes of the cancer stem cell (CSC) division when one considers survival of CSC with proliferation potential i (CSC _{i}). (B) Probability of spontaneous tumor remission, P , described by Eqn. (A), for different values of probability that the non-stem cancer cell will die before proliferation attempt, α' , and plasticity event frequencies, $p_d = p_{dd}$. (C) Spontaneous remission of all 100 simulated tumors initiated with single CSC equipped with proliferation capacity $\rho = 3$ and probability of symmetric division $p_s = 1\%$. (D) Spontaneous remission of 17 out of 100 simulated tumors initiated

with single CSC equipped with proliferation capacity $\rho = 3$ and probability of symmetric division $p_s = 3\%$.

Figure 4. (A) Simulation snapshots of the biggest tumor at $t = 720$ days for each consider plasticity event probability. s : number of cancer stem cells; n : number of cancer cells. Comparison of circularity (B), percent of quiescent cells (C), and cancer stem cells fraction in $200\mu\text{m}$ proximity of tumor boundary (D) for different probabilities of plasticity event. Shown are means \pm SD from 100 simulation runs (only successfully grown tumors are considered).

Figure 5. (A) Average \pm SD number of days until the right boundary of 5-well plate is reached by cancer stem cell for different probabilities of plasticity event (p_d). (C) Simulation snapshots at the moment when first cancer stem cell reach the right boundary for different probabilities of plasticity event (p_d). Percentages above each well indicate the fraction of cancer stem cells within each well.

Figure 6. Response to radiotherapy (RT) consisted of $30 \times 2\text{Gy}$ dose applied every day of tumors with about 250,000 initial cell count for different probabilities of plasticity event (p_d). (A) Average radiation response. (B) Regrowth for low p_d . (C) Remission for $p_d = 10\%$. $N = 10$ simulations.




Figure 1.




Figure 2.




Figure 3.




Figure 4.




Figure 5.




Figure 6.

Appendix

Probability of early tumor death event

We set on to approximate analytically the probability that the initial CSC with proliferation capacity ρ will differentiate before first symmetric division and all of its non-stem progenies will die before any de-differentiation event, which we denote as D_ρ . We consider a very early stage of tumor development and, thus, we can neglect space inhibition (we have large migration probability of 15/24). The probability that non-stem cell with given proliferation potential, ρ , and all its progenies won't de-differentiate before dying off, ω_ρ , follows recurrence relation

$$\omega_\rho = \frac{\alpha}{\alpha + (1-\alpha)p_p} + \frac{(1-\alpha)(1-p_{dd})p_p}{\alpha + (1-\alpha)p_p} \omega_{\rho-1}^2,$$

with $\omega_0 = 1 - p_p(1-\alpha)p_{dd}/(\alpha+p_p(1-\alpha))$. The probability that the CSC will undergo differentiation before first symmetric division is equal to $p_d/((1-p_d)p_s+p_d)$ and the number of non-symmetric divisions follows geometric distribution with probability of success $p = (1-p_d)p_s+p_d$. Thus, we obtain the following expression for D_ρ

$$D_\rho = p_d \omega_{\rho-1}^2 \sum_{k=0}^{\infty} \omega_\rho^k (1 - (1-p_d)p_s - p_d)^k = \frac{p_d \omega_{\rho-1}^2}{1 - \omega_\rho (1 - (1-p_d)p_s - p_d)}.$$

In Fig. A1 we plotted D_ρ under the assumption that $p_d=p_{dd}$ and for parameters considered in the main text. We see that for all considered plasticity event probabilities the probability of early tumor death is close to 0.5%. It is worth to notice that if spatial inhibition will increase value D_ρ more for lower probabilities of plasticity event, as on average more non-stem progenies are created before differentiation event.




Figure A1. Probability of early tumor death event for different plasticity event probability and for parameters considered in the main text.